Bildkälla: Stockfoto

Active Biotech: Tasquinimod advances into combination therapy - Redeye

Redeye comments on the clinical development of Tasquinimod, which has concluded the single-agent dose-escalation arm in multiple myeloma.

Redeye comments on the clinical development of Tasquinimod, which has concluded the single-agent dose-escalation arm in multiple myeloma.
Börsvärldens nyhetsbrev
ANNONSER